DV
Dynavax Technologies Corporation
DVAX · NASDAQ
$15.50 +0.00% (+$0.00)
Market Cap $1.82B
P/E Ratio -
Div. Yield -
ROE 8.05%
Bulios Fair Price
$15.37
0.8% downside
Current Price
$15.5
Undervalued Fair Value Overvalued
According to Bulios Fair Price, DVAX is currently trading close to its fair value. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
54 /100
Fair P/B 3.41x
P/FCF 22.60x
P/S 5.51x
Growth
100 /100
Growing Book val. growth 312.30%
Rev. growth 173.77%
FCF growth N/A
Profitability
54 /100
Moderate Net margin 13.13%
Op. margin 3.16%
FCF margin 24.37%
Quality
5 /100
Poor ROE 8.05%
ROA 4.59%
Asset turnover 0.35x
Debt
74 /100
Low Current ratio 7.62x
Int. coverage -5.28x
Net debt/EBITDA -4.86x
Stability
27 /100
Unstable Rev. volatility 459.67%
EPS volatility 92.02%
Profitable years 1
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about DVAX
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Ryan Spencer
Employees
405
Headquarters
EmeryVille